Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy.
10.1016/j.apsb.2021.01.017
- Author:
Yanan LI
1
;
Cangang ZHANG
2
;
Guo LI
3
;
Guowei DENG
4
;
Hui ZHANG
1
;
Yongbing SUN
5
;
Feifei AN
3
Author Information
1. College of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China.
2. Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China.
3. Institute of Medical Engineering, Department of Biophysics, School of Basic Medical Science, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
4. College of Chemistry and Life Science, Institute of Functional Molecules, Chengdu Normal University, Chengdu 611130, China.
5. Division of Pharmaceutics, National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China.
- Publication Type:Review
- Keywords:
Drug delivery;
Malignancy;
Multifunctional construction;
Nanomedicine;
Precise diagnosis;
Protease-responsive;
Synergistic theranostic;
Targeted therapy
- From:
Acta Pharmaceutica Sinica B
2021;11(8):2220-2242
- CountryChina
- Language:English
-
Abstract:
Proteases have a fundamental role in maintaining physiological homeostasis, but their dysregulation results in severe activity imbalance and pathological conditions, including cancer onset, progression, invasion, and metastasis. This striking importance plus superior biological recognition and catalytic performance of proteases, combining with the excellent physicochemical characteristics of nanomaterials, results in enzyme-activated nano-drug delivery systems (nanoDDS) that perform theranostic functions in highly specific response to the tumor phenotype stimulus. In the tutorial review, the key advances of protease-responsive nanoDDS in the specific diagnosis and targeted treatment for malignancies are emphatically classified according to the effector biomolecule types, on the premise of summarizing the structure and function of each protease. Subsequently, the incomplete matching and recognition between enzyme and substrate, structural design complexity, volume production, and toxicological issues related to the nanocomposites are highlighted to clarify the direction of efforts in nanotheranostics. This will facilitate the promotion of nanotechnology in the management of malignant tumors.
